The Nuclear Medicine Radiopharmaceuticals Market is predicted to reach $ 8.44 billion USD with a CAGR of 13.4% according to Market Data Forecast report.

The Nuclear Medicine Radiopharmaceuticals Market is predicted to reach $ 8.44 billion USD with a CAGR of 13.4% according to Market Data Forecast report.

ID: 170 | October 2018 | Region: Global


The Nuclear Medicine Radiopharmaceuticals Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Nuclear Medicine Radiopharmaceuticals Market is estimated to be $4.5 billion USD and predicted to reach to  $ 8.44 billion USD with a CAGR of 13.4%. The market is segmented by Diagnostic radioisotopes (SPECT and PET), Therapeutic radioisotopes (Beta emitters, Alpha Emitters and Brachytherapy), and application (cardiology, lymphoma, thyroid, neurology, oncology, and others). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa

Increasing incidence of cancer and cardiac ailments, huge technological advancements, growing demand for SPECT and PET applications and also the mounting public awareness are fuelling the market growth for Radiopharmaceuticals. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as an excellent diagnostic tool in medical imaging and is considered to be a major driving factor for the growth of Nuclear Medicine Radiopharmaceuticals Market.

Radiopharmaceuticals market is dominated by diagnostic radioisotopes while therapeutic radioisotopes account for a minor share as the therapeutic radioisotopes market is recently evolving and has a great potential of growth in the forecast period. By application oncology segment accounted for the largest share due to growing prevalence of various cancers. Cardiology segment is estimated to be the fastest growing segment owing to the increase number of cardiac related diseases.

North America is the dominant market for radiopharmaceuticals accounting for a share of approximately 34% of the Global Nuclear Medicine radio pharmaceuticals market. Asia-Pacific is estimated to be the fastest growing segment owing to the rising healthcare and increasing demand for different radioisotopes in various treatments and applications.

Some of the major players influencing the global nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.

 Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/” and checkout our recent reports in the Pharmaceuticals category at “http://www.marketdataforecast.com/research-reports/healthcare/pharmaceuticals-1/”. For more insights and up-to-date industry news doesn’t forget subscribing to our newsletters.

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.